At a glance
- Menotropins (hMG) is an FDA-approved drug, marketed as Menopur (first approval: October 29, 2004).
- PubMed lists 1,561 publications mentioning it, including 150 randomized controlled trials and 71 animal-only studies.
- ClinicalTrials.gov lists 142 registered studies testing it (10 active).
- FDA's adverse event system (FAERS) holds 2,130 reports mentioning it; 1,049 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
| Application | Product | Status | First approval | Sponsor |
|---|---|---|---|---|
| BLA017646 | PERGONAL | Approved, discontinued | August 22, 1975 | SERONO |
| BLA020328 | HUMEGON | Approved, discontinued | September 1, 1994 | ORGANON USA INC |
| BLA021047 | REPRONEX | Approved, discontinued | August 27, 1999 | FERRING |
| BLA021663 | MENOPUR | Approved, marketed | October 29, 2004 | FERRING |
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Follitropin delta versus human menopausal gonadotropin in progestin protocol cycles: a retrospective cohort study using inverse probability of treatment weighting.
- Real-world utilization of gonadotropins and the associated cumulative live birth rates in the United States: a retrospective claims database analysis.
- Effectiveness and Patient Compliance of a Needle-Free Injection System in Controlled Ovarian Stimulation in IVF Cycles: A Real-World, Investigator-Initiated, Retrospective, Multicenter, Observational Study.
- Is there a difference in ovarian hyperstimulation syndrome rates in freeze-all treatment cycles in high-risk patients treated with different GnRH agonist triggers?
- Optimizing ovarian stimulation in oocyte donation: exploratory comparison of rhFSH (2:1) versus hp-hMG under PPOS protocols.
- Re-assessment of the therapeutic LH window in normogonadotropic IVF patients.
- Impact of Family Planning Program on Related Drug Consumption in Iran: A Ten-Year Trend Analysis (2014 - 2023).
- Mature oocyte retrieval without an exogenous trigger during random-start stimulation in a very early intrauterine pregnancy: a case report.
- The Historical and Contemporary Significance of Gonadotropins: Insights from Avicenna and Modern Science.
- Effect of alpha-lipoic acid supplementation on polycystic ovary syndrome clinical outcome in infertile females treated with letrozole: a randomized controlled trial.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 142
- Active
- 10
- With posted results
- 18
Conditions studied
Show 40 more studies
All 142 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 2,130
- Serious
- 1,049
- With death outcome
- 34
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
FDA prescribing information
Official US prescribing information. Dosing sections are intentionally not shown.
Source: DailyMed / openFDA
Change history
No changes since monitoring began on October 30, 2026.